NCT06383182 Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion
| NCT ID | NCT06383182 |
| Status | Recruiting |
| Phase | — |
| Sponsor | General Hospital of Shenyang Military Region |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-07-02 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-07-02 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-80 years; 2. Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment; 3. Pre-stroke mRS: 0-1; 4. Baseline NIHSS: ≥6; 5. Signed informed consent. Exclusion Criteria: 1. The presence of contraindications to internal jugular vein cannulation; 2. Receiving intravenous thrombolysis; 3. Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage); 4. Coagulation disorders, systemic bleeding tendency, thrombocytopenia (\<100×109/L); 5. Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases; 6. Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg); 7. Pregnant or lactating women; 8. Other conditions who are not suitable for this trial by investigator.
Frequently Asked Questions
Who can join the NCT06383182 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06383182 currently recruiting?
Yes, NCT06383182 is actively recruiting participants. Visit ClinicalTrials.gov or contact General Hospital of Shenyang Military Region to inquire about joining.
Where is the NCT06383182 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06383182 clinical trial?
NCT06383182 is sponsored by General Hospital of Shenyang Military Region. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.